What is happening in skin affected by vitiligo?
Vitiligo is a chronic autoimmune disorder in which melanocytes, the cells that make pigment, are attacked and lost or impaired. The visible result is depigmentation: areas that have lost their natural color. Evidence Evidence Evidence This statement has a dated source and is waiting for a clinician's sign-off. Pending clinical review
Why this matters
- Reasonably supported
Melanin made by melanocytes contributes color to skin and hair. The clinical sources I read describe autoimmunity as central to vitiligo, while recognizing that the biological pathway is more complex than a single cause or event.
Considerations
- Depends on you
This mechanism does not explain why a particular patch appeared in a particular place or why one person’s course differs from another’s. A general mechanism is not an individual forecast.
Questions for your clinician
How sure are you that this is vitiligo?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Does my history change how you interpret it?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Can vitiligo affect more than the skin?
Vitiligo can involve pigment in skin, hair, and mucous membranes. It can also affect wellbeing, and clinicians may consider associated autoimmune conditions as part of a person’s broader medical context. Evidence Evidence Evidence This statement has a dated source and is waiting for a clinician's sign-off. Pending clinical review
Why this matters
- Reasonably supported
NIAMS describes depigmented skin, whitening of hair in affected areas, and possible involvement inside the mouth or nose. The clinical guidance I read also treats psychosocial impact and relevant autoimmune history as meaningful parts of assessment, rather than dismissing vitiligo as only cosmetic.
Considerations
- Depends on you
Having vitiligo does not mean a person has, or will develop, every associated condition. Whether symptoms or history justify further evaluation is an individual clinical decision.
Questions for your clinician
Does my personal or family history suggest any additional evaluation?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Can my daily life shape our goals and options?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What do “segmental” and “nonsegmental” mean?
They describe clinical patterns, not a severity score. Segmental vitiligo has a characteristic segment-like distribution, while nonsegmental vitiligo is the umbrella category for other recognized patterns; mixed and not-yet-classified presentations also exist. Evidence Evidence
Why this matters
- Sources cited, not yet graded
The international consensus I read separates segmental vitiligo from other forms, because the distinction can matter for prognosis and management discussions. The same consensus recognizes that a localized patch may remain unclassified until its clinical pattern becomes clearer.
Considerations
- Depends on you
Pattern names can be difficult to apply from a single patch or photograph, and terminology has changed across publications. A clinician may reasonably defer classification instead of forcing an early label.
Questions for your clinician
Which pattern fits, and how certain is that?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Would the pattern change the options or follow-up you would discuss?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Will vitiligo spread?
One snapshot cannot predict whether an individual’s vitiligo will remain stable, change, or where a new patch might appear. Clinicians assess apparent activity from the history, examination, and change observed across follow-up - not from a promise about the future. Evidence Evidence Evidence This statement has a dated source and is waiting for a clinician's sign-off. Pending clinical review
Why this matters
- Reasonably supported
Vitiligo courses vary, and the classification guidance I read keeps pattern and disease stability apart. Recording new areas and changes in existing areas can give a clinician better evidence for describing what has happened so far.
Considerations
- Depends on you
Past stability does not guarantee future stability, and a recent change does not reveal the entire future course. Even the definition and assessment of stability have limitations, especially when reduced to a single whole-body label.
Questions for your clinician
What evidence are you using to describe my vitiligo as active or stable?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What changes would be useful to record before follow-up?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What causes vitiligo?
The best-supported explanation involves autoimmunity interacting with genetic susceptibility and other biological or environmental factors. There is no single behavior, food, stressful event, or personal mistake that explains every case. Evidence Evidence This statement has a dated source and is waiting for a clinician's sign-off. Pending clinical review
Why this matters
- Reasonably supported
NIAMS describes vitiligo as autoimmune, and notes that researchers continue to study how genes, family history, and possible triggering events contribute. I have not found a source that turns any of that into something you did wrong. “Associated with” or “noticed after” does not by itself prove that one event caused the condition.
Considerations
- Depends on you
Science has not reduced vitiligo to one universal cause, and an individual’s exact trigger may never be knowable. That uncertainty should not be filled with blame or an unsupported detoxification, diet, or cure story.
Questions for your clinician
Which parts of my history matter medically?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Which explanations have good evidence, and which are only hypotheses?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Is vitiligo contagious - and must it be treated?
Vitiligo is not an infection and cannot be caught from another person. Treatment is a choice: some people pursue repigmentation or control of change, some use camouflage or supportive care, and some choose no active treatment. Evidence Evidence Evidence This statement has a dated source and is waiting for a clinician's sign-off. Pending clinical review
Why this matters
- Reasonably supported
One of the questions patients raise most is whether they are contagious, and whether other people will assume they are. The autoimmune mechanism means vitiligo is not spread by touch or shared spaces. The dermatology guidance I read recognizes that goals differ. It also treats a diagnosis as the start of an informed discussion, not an assumption that every person wants the same outcome.
Considerations
- Depends on you
Choosing whether to treat can change as the condition, health, access, or personal priorities change. The diagnosis alone does not identify a single best option for an individual.
Questions for your clinician
What choices fit the goals I have right now, including no active treatment?
Saving keeps this on your device and needs JavaScript, which is off in this browser.How would we revisit the plan if my priorities change?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence and update context
This optional layer shows the evidence boundary I reviewed as of 2026-09-19.
- What this evidence supports
- Melanin made by melanocytes contributes color to skin and hair. The clinical sources I read describe autoimmunity as central to vitiligo, while recognizing that the biological pathway is more complex than a single cause or event.
- What it does not establish
- This mechanism does not explain why a particular patch appeared in a particular place or why one person’s course differs from another’s. A general mechanism is not an individual forecast.
Pending clinical review
This statement has a dated source and is waiting for a clinician's sign-off.
Pending clinical review
This statement has a dated source and is waiting for a clinician's sign-off.
Pending clinical review
This statement has a dated source and is waiting for a clinician's sign-off.
Pending clinical review
This statement has a dated source and is waiting for a clinician's sign-off.
Pending clinical review
This statement has a dated source and is waiting for a clinician's sign-off.
Pending clinical review
This statement has a dated source and is waiting for a clinician's sign-off.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- Journal of the European Academy of Dermatology and VenereologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making. Its modified assessment check list names where the patches are as a disease feature, and gives genital involvement as its own example. It records white hairs as an item of its own, apart from what the vitiligo has done in the past six months. Its classification table keeps mucosal vitiligo as a subtype, both across more than one site and at one site alone. It supports planning care around what is there to work with, and its example is hair that still has its color. It names stable vitiligo and active vitiligo as two different states that change the care plan. Its shared-decision steps ask what the patient wants from care. At the time it was written, one cream form of a newer drug type had just been approved. Pill forms of that same drug type were still being studied.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph. It gives no figure for genital involvement, and it does not name lichen sclerosus. It does not set out the Vitiligo European Task Force grading scale. It puts no figure on white hairs and predicts nothing for one person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Eleftheriadou V, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence. Its classification table defines mucosal vitiligo as the oral or genital mucosae. One mucosal site alone is filed as undetermined or unclassified. Its differential diagnosis table lists genital or extragenital lichen sclerosus among the conditions that can be mistaken for vitiligo. That table also lists eczema, psoriasis, lichen planus, pityriasis alba and piebaldism. It calls autoimmunity a contributor to the pathogenesis of vitiligo. It reports an earlier review finding a possible negative impact on intimacy and sexual functioning. It tells clinicians to discuss the psychosocial impact of living with the condition. R28 offers a skin camouflage visit to people who want one. R10 to R14 name potent or very potent topical steroids as the first choice, with a topical calcineurin-inhibitor cream as an option for the face. These are different creams with different proof behind them. R20 names narrowband UVB as the first light option. It says the skin often does better on the face and trunk than on hands and feet. It says there is not enough proof to use any one current pill alone for vitiligo that is not changing. R25 and Table 2 keep cell grafting for vitiligo that is not changing and did not respond to other care. They also say a doctor cannot always tell if the vitiligo has truly stopped changing.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage. Its differential diagnosis table is a list, not a method a reader can apply to their own skin. It does not say how to tell any two of those conditions apart. It gives no figure for how often vitiligo affects genital skin.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports a patient-facing description of clinician diagnosis using history and examination, possible use of a Wood lamp and selected tests, broad treatment categories, variable response and whole-person support.
What it does not support
It is educational context, not primary efficacy evidence, an online diagnostic method or a universal testing checklist.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Pigment Cell & Melanoma Research (Ezzedine K, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports separating segmental vitiligo from nonsegmental forms and recognizing mixed and initially unclassified presentations. Classification is a clinical and longitudinal judgment. Its section on the Koebner phenomenon supports defining that phenomenon as patches developing at sites of previously unaffected skin that was specifically injured. It endorses the Vitiligo European Task Force classification of that phenomenon into history-based, clinical-observation-based and experimentally induced forms. Its section on mucosal vitiligo defines that term as the oral or genital mucosae. Where the patches are at one site alone, and especially a genital one, that section says a differential diagnosis of lichen sclerosus should be addressed by biopsy. It records that genital lichen sclerosus and vitiligo have been reported together.
What it does not support
It does not support self-classification from symmetry, one patch or a photograph, and it does not predict an individual response. On the Koebner phenomenon it records a general impression that the phenomenon and disease stability are related, then states that objective data are lacking. It also says scientific evidence is lacking for attributing vitiligo to daily friction from washing, dressing, personal care, sports, occupational activity or pressure from clothing. On lichen sclerosus it cites one reference from 2000 and calls a link a possibility, not a finding. It counts nothing and gives no rate.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports current US patient-language context that lighter patches have multiple causes, dermatologists diagnose vitiligo from history and examination, treatment is optional and several broad management paths exist.
What it does not support
The page acknowledges support from Incyte Dermatology, so it does not independently establish drug efficacy or comparative superiority.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.